It’s One Thing to Hate Needles, Another to Hate the Needle Filled with the Medicine Prescribed to the Patient in the Next Room (MFTH)

You are certainly not alone if you struggle with watching (hopefully) a medical practitioner readying a needle for the introduction of clear liquid into your IV, or even directly in to your vein. Equally, or perhaps even more frightening, is that there exist many occasions when you will not be in possession of the faculties sufficient to observe the same administration and question what you are about to receive. Little things like comas and sleep. While you are probably not a doctor, there is something reassuring about being able to ask what you are to be injected with, if for no other reason than the inherent comfort in giving the needle wielder a moment to think.

Medisafe 1 Technologies (OTC: MFTH) knows how you feel. More importantly, it has developed a syringe locking system that requires both a database and barcode failsafe mechanism and also an override in order to physically function. Read: You won’t accidently be given 200ccs of insulin following a simple tonsillectomy.

The scope of these “accidental deliveries” by syringe is truly frightening. Just as Truman Capote’s “In Cold Blood” brought to light the absurdity and consequences of being rumored to keep valuables in the home, there are a numerous studies that make the hair on your neck stand straight up in the air when examined. The sheer movement of Medisafe’s stock, however, takes precedence.

Medisafe 1 Technologies gained $0.0027 in yesterday’s trading. While that number remains well below a single cent of movement, it accounted for a gain of an even 180%. You do the math. That was a staggering day of trading on a volume over 123 million shares changing hands. Numbers like these should never be looked at as less than nearly tripling your investment in a single day.

The stock traded steadily on the rise from yesterday’s opening bell. Closing the day at $0.0042 after opening at absolute zero, but finding its way to a low of $0.0015.

The aforementioned scary truths spoken of earlier? In a paper published online by Dr. Andreas Valentin in The British Medical Journal (2009) look at a few things he found in his 24-hour study of 113 ICU units in 27 countries:

“Valentin and his team found from their research was that, in a total of 1,328 patients, 861 errors affecting 441 patients were reported over the 24-hour period. Just over two thirds (67%) of patients experienced no error, 250 patients (19%) experienced only one error and 191 patients (14%) experienced more than one error. Although 71% of the errors resulted in no change in the status of the patient, 12 patients (0.9% of the total study population) suffered permanent harm or death related to a total of 15 medication errors that occurred at the administration stage. Trainees were reported as being involved in eight of these errors.

The most frequent mistakes related to wrong time of administration (386) and missed medication (259), followed by wrong dose (118), wrong drug (61), and wrong route (37). Workload / stress / fatigue was reported by ICU staff as a contributing factor in 32% of all errors. Other contributing factors included a recently changed drug name (18%), communication – written (14%), communication – oral (10%) and violation of standard protocol (9%).”

This is nothing short of staggering. Look to Medisafe to use the hundreds of similar reports available to make sure its stock continues to shoot for properly administered stars.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email ( or his Google+ page (